PlumeSTARS
PlumeSTARS is an innovative SME founded in September 2013, specializing in designing and developing dry powders for inhalation through particle engineering. It is based on the expertise of its founders and the Biopharmanet-TEC, Interdepartmental Centre for Innovation in Health Products of the University of Parma, Italy. The company focuses on the development of orphan medicines, including antibiotics for inhalation, implantable chemotherapeutic agents, and oral and nasal drugs, leveraging knowledge in pharmaceutical particle engineering, micro and nanoparticle technology, drug delivery, and inhalation products.
Industries
Nr. of Employees
small (1-50)
PlumeSTARS
Patents
Powder composition based on microparticles embedding nanoparticles for the delivery of therapeutic/diagnostic compounds
US-12357572-B2
View Details
Powder composition based on microparticles embedding nanoparticles for the delivery of therapeutic/diagnostic compounds
US-12357572-B2
View DetailsProducts
Thalidomide (development for orphan indications)
Development activities and regulatory documentation related to thalidomide for orphan indications, with EMA public summaries and committee opinions available.
Cisplatin (development for orphan indications and delivery formats)
Development information and EMA orphan designation documentation for cisplatin, including exploration of alternative delivery formats.
Amikacin (development for inhalation/orphan indications)
Development activities and regulatory material related to amikacin for orphan designations and inhalation delivery.
Tobramycin (development for inhalation/orphan indications)
Referenced as part of aminoglycoside development activities for inhalation delivery; related product documentation is available.
Thalidomide (development for orphan indications)
Development activities and regulatory documentation related to thalidomide for orphan indications, with EMA public summaries and committee opinions available.
Cisplatin (development for orphan indications and delivery formats)
Development information and EMA orphan designation documentation for cisplatin, including exploration of alternative delivery formats.
Amikacin (development for inhalation/orphan indications)
Development activities and regulatory material related to amikacin for orphan designations and inhalation delivery.
Tobramycin (development for inhalation/orphan indications)
Referenced as part of aminoglycoside development activities for inhalation delivery; related product documentation is available.
Services
Formulation design, particle engineering and development of dry powder inhalation products for pulmonary delivery.
Preparation and provision of documentation related to orphan medicinal product designation and engagement with regulatory public summaries and opinions.
Participation in collaborative research projects and consortia to advance product and technology development.
Formulation design, particle engineering and development of dry powder inhalation products for pulmonary delivery.
Preparation and provision of documentation related to orphan medicinal product designation and engagement with regulatory public summaries and opinions.
Participation in collaborative research projects and consortia to advance product and technology development.
Expertise Areas
- Inhalation drug formulation
- Particle engineering and micro/nanoparticle technologies
- Orphan drug development
- Respiratory antibiotic development
Key Technologies
- Particle engineering
- Dry powder inhalation formulation
- Micro- and nanoparticle technology
- Inhalation drug delivery